AbbVie’s next-generation Crohn’s disease combination candidate has beaten Skyrizi in a midphase clinical trial. Skyrizi is a ...

Nouscom has reeled in 120 million euros ($135 million) in series D funds to take a cancer-preventing vaccine through a ...

Paradromics has announced a new collaboration with Siemens Healthineers to construct an advanced multimodal imaging platform ...

As Washington ramps up efforts to tighten cross-border life sciences deals involving Chinese assets, Beijing is moving to ...

When Fierce last caught up with OMass Therapeutics’ CEO Ros Deegan, it was hard not to be impressed by the company’s ambition ...

Frazier Life Sciences also hit the Nasdaq on Friday with its second biotech-focused special purpose acquisition company (SPAC ...

Estuary Biotherapeutics has swum out of stealth with $103 million in funding to power a pair of gene therapies into clinical ...

Iambic Therapeutics’ IPO came in dead on target, bringing in $150 million for the AI biotech to fuel the clinical development ...

Verdiva Bio has scrapped a phase 2 trial of its once-weekly oral GLP-1 drug candidate VRB-101. | Verdiva Bio has scrapped a ...

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the ...

Looking to expand its oncology portfolio, Gilead Sciences has tapped Vir Biotechnology’s masked T-cell engager (TCE) tech in ...

Labcorp has launched the Thrive 5 Health Test that is now offered through a collaboration with Arianna Huffington's behavior ...